FLUXID
LOE ApproachingNDAORALTABLET, ORALLY DISINTEGRATING
Approved
Sep 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
FLUXID by UCB Pharma is clinical pharmacology in adults gi effects famotidine is a competitive inhibitor of histamine h 2 -receptors. First approved in 2004.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FLUXID is an orally disintegrating tablet formulation of famotidine, a competitive H2-receptor antagonist that inhibits gastric acid secretion. It is indicated for the treatment of duodenal ulcers and related GI acid-related disorders by suppressing both basal and stimulated gastric acid production. The drug achieves its maximum antisecretory effect within 1–3 hours and maintains inhibition for 10–12 hours per dose.
LOE Approaching
Product is in late-stage lifecycle with declining commercial investment; brand teams are typically consolidating and focusing on retention rather than expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY IN ADULTS GI Effects Famotidine is a competitive inhibitor of histamine H 2 -receptors. The primary clinically important pharmacologic activity of famotidine is inhibition of gastric secretion. Both the acid concentration and volume of gastric secretion are suppressed by…
Worked on FLUXID at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.